Sign Up Today and Learn More About Genomind Stock
Invest in or calculate the value of your shares in Genomind or other pre-IPO companies through EquityZen's platform.
Genomind Stock
Genomind is a personalized medicine company specializing in neuropsychiatry.
About Genomind Stock
Founded
2009
Headquarters
Chalfont, PA, US
Industries
Professional Services, Science and Engineering, Health Care
Genomind is a personalized medicine company specializing in neuropsychiatry. It was founded by a psychiatrist, Dr. Ronald Dozoretz, and a neurologist, Dr. Jay Lombard, who share a common goal of wanting the best possible care for patients who suffer from psychiatric illness. It was founded in 2009 and headquartered in Chalfont, Pennsylvania.
Genomind Press Mentions
Stay in the know about the latest news on Genomind
Systems and methods for identifying and reporting genetic predispositions …
patents • Feb 16, 2025
Precision Medicine Software Market Report 2024-2029: Industry Trends, Business Opportunities, Competitive Intelligence, Regional Growth Forecasts
globenewswire • Oct 31, 2024
Methods and systems for reporting patient- and drug-specific medical data
patents • Apr 15, 2024
Detection of specific hla alleles
patents • Apr 15, 2024
Systems and methods for identifying and reporting genetic predispositions …
patents • Apr 15, 2024
Genomind Management
Leadership team at Genomind
Founder
Ronald I. Dozoretz
Director of Behavioral Science
Francis Brennan
Join now and verify your accreditation status to gain access to:
- Genomind Current Valuation
- Genomind Stock Price
- Genomind Management
- Available deals in Genomind and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Genomind Cap Table and Funding History by Share Class and Liquidity Preferences
- Genomind Revenue and Financials
- Genomind Highlights
- Genomind Business Model
- Genomind Risk Factors
- Genomind Research Report from SACRA Research
Trading Genomind Stock
How to invest in Genomind stock?
Accredited investors can buy pre-IPO stock in companies like Genomind through EquityZen funds. These investments are made available by existing Genomind shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Genomind stock?
Shareholders can sell their Genomind stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
